Previous 10 | Next 10 |
MediciNova (MNOV) has announced clinical findings published in Cancer Chemotherapy and Pharmacology, related to MN-166 (ibudilast) as a treatment for prevention of chemotherapy-induced peripheral neuropathy ((CIPN)).14 patients completed two cycles of chemotherapy, including on...
LA JOLLA, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive clinical findings published in Cancer Chemoth...
Gainers: American Well (AMWL) +17%, MediciNova (MNOV) +13%, Mallinckrodt (MNK) +7%, Capricor Therapeutics (CAPR) +8%, Adamas Pharmaceuticals (ADMS) +6%.Losers: AC Immune (ACIU) -42%, Wave Life Sciences (WVE) -34%, Rockwell Medical (RMTI)&...
SPI Energy (SPI) +56% after launching new EV Company.MediciNova (MNOV) +36% on positive intranasal COVID-19 vaccine data.vTv Therapeutics (VTVT) +20% on positive clinical study results supporting the safety and efficacy of TTP399.Athersys (ATHX) +13% af...
MediciNova (MNOV) rallies 28% premarket on robust volume in reaction to encouraging preclinical data on its intranasal COVID-19 vaccine candidate, BC-PIV SARS-CoV-2.Results from a mouse study showed that the vaccine induced high titers of serum IgG and mucosal IgA neutralizing antib...
LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its intranasal SARS-CoV-2 vaccine prototype for COV...
Vascular Biogenics (NASDAQ: VBLT ) +32% on strong preclinical results of MOSPD2 program. More news on: Vascular Biogenics Ltd., Genetic Technologies Limited, Eastman Kodak Company, Stocks on the move, , Read more ...
MediciNova (NASDAQ: MNOV ) is up 13% premarket on light volume in reaction to the announcement of encouraging preclinical results on an intranasal RSV vaccine by SARS-CoV-2 vaccine development partner BioComo. More news on: MediciNova, Inc., Healthcare stocks news, Stocks o...
LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that BioComo, co-developer of MediciNova’s SARS-C...
It's been a while since I went through the whole vaccine landscape (I've been putting it off!), but there's a lot to catch up on. I'm going to incorporate some slightly reworked material from my July post in the introduction to each vaccine class, for reference, but everything on the candida...
News, Short Squeeze, Breakout and More Instantly...
Company to rededicate efforts toward updating stakeholders on corporate vision, strategy, and ongoing activities LA JOLLA, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market o...
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S....
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Gilbert Youssef, M.D....